Gemcitabine 200 Mg Oethmaan, Gemcitabine 1 G Oethmaan 200 mg, 1 g Powder for solution for infusion.
PDF Leaflet Revision Date: 09 December 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including non-small cell lung cancer and pancreatic cancer.
Dosage (summary)
1,000 mg/mu00b2 IV infusion over 30 mins, weekly for 3 weeks, then 1 week rest.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Not established; contraindicated in pregnancy and lactation.
Key Drug Interactions
- Cisplatin
- Paclitaxel
- Radiotherapy
Contraindications
- Hypersensitivity to gemcitabine
- Pregnancy
- Lactation
- Children
Common side effects
- Nausea
- Vomiting
- Leucopenia
- Thrombocytopenia
- Allergic skin rash
Counselling Points
- Monitor for signs of infection
- Use effective contraception
- Avoid live vaccines
Serious warnings
- Myelosuppression
- Capillary leak syndrome
- Posterior reversible encephalopathy syndrome
Important Disclaimer
The Gemcitabine 200 Mg Oethmaan, Gemcitabine 1 G Oethmaan 200 mg, 1 g Powder for solution for infusion. professional information leaflet below is the property of Oethmaan Biosims and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
